Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First in Human, Double-blind, Placebo-controlled, Multicentre Phase I/II Study to Evaluate the Safety, Tolerability and Immune Modulatory Effects of MRx-4DP0004 in Participants Taking Long-term Control Medication for Their Asthma

NCT03851250 is registered in ClinicalTrials.gov with 4D pharma plc as lead sponsor.

NCT NCT03851250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03851250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First in Human, Double-blind, Placebo-controlled, Multicentre Phase I/II Study to Evaluate the Safety, Tolerability and Immune Modulatory Effects of MRx-4DP0004 in Participants Taking Long-term Control Medication for Their Asthma
Lead sponsor
4D pharma plc
Phase
Phase 1
Overall status
Terminated
Start date
July 4, 2019
Completion date
April 26, 2023
Enrollment
34 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

asthma